RPAM
APLS

Rhenman & Partners Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-374,450
Closed -$9.41M – 88
2025
Q4 		$9.41M Buy
374,450
+142,200
+61% +$3.34M 0.88% 46
2025
Q3 		$5.26M Buy
232,250
+139,000
+149% +$3.24M 0.58% 52
2025
Q2 		$1.61M Buy
93,250
+65,000
+230% +$1.2M 0.2% 76
2025
Q1 		$618K Sell
28,250
-167,341
-86% -$4.62M 0.07% 91
2024
Q4 		$6.24M Sell
195,591
-171,909
-47% -$5.17M 0.64% 49
2024
Q3 		$10.6M Buy
367,500
+312,105
+563% +$11.6M 0.86% 39
2024
Q2 		$2.12M Sell
55,395
-123,000
-69% -$5.57M 0.2% 73
2024
Q1 		$10.5M Buy
178,395
+77,995
+78% +$4.97M 0.99% 33
2023
Q4 		$6.01M Sell
100,400
-114,600
-53% -$5.81M 0.6% 55
2023
Q3 		$8.18M Buy
215,000
+25,000
+13% +$1.1M 0.88% 39
2023
Q2 		$17.3M Buy
190,000
+5,000
+3% +$431K 1.82% 24
2023
Q1 		$12.2M Sell
185,000
-15,000
-8% -$866K 1.34% 28
2022
Q4 		$10.3M Sell
200,000
-20,000
-9% -$1.06M 1.08% 35
2022
Q3 		$13.3M Buy
220,000
+10,000
+5% +$592K 1.39% 28
2022
Q2 		$9.5M Sell
210,000
-167,000
-44% -$7.61M 1.08% 35
2022
Q1 		$19.2M Sell
377,000
-53,000
-12% -$2.34M 1.89% 18
2021
Q4 		$20.6M Sell
430,000
-131,269
-23% -$5.17M 1.37% 27
2021
Q3 		$18.5M Buy
561,269
+256,269
+84% +$14.4M 1.3% 34
2021
Q2 		$19.3M Buy
305,000
+35,000
+13% +$1.81M 1.31% 34
2021
Q1 		$11.6M Hold
270,000
– – 0.81% 45
2020
Q4 		$15.4M Buy
270,000
+45,000
+20% +$1.9M 1.26% 34
2020
Q3 		$6.79M Buy
225,000
+60,000
+36% +$1.79M 0.6% 55
2020
Q2 		$5.39M Buy
165,000
+65,000
+65% +$2.09M 0.58% 58
2020
Q1 		$2.68M Buy
100,000
+20,000
+25% +$710K 0.38% 70
2019
Q4 		$2.45M Buy
+80,000
New +$2.21M 0.27% 79

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Rhenman & Partners Asset Management's APLS Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 374,450 shares — an estimated $9.41M sold.

Rhenman & Partners Asset Management first reported a position in APLS in Q4 2019 and held it in 25 quarters. The position peaked at $20.6M in Q4 2021. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Rhenman & Partners Asset Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 374,450 Apellis Pharmaceuticals shares in Q1 2026, an estimated $9.41M.
  • Rhenman & Partners Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 25 quarters.
  • Rhenman & Partners Asset Management's Apellis Pharmaceuticals position peaked at $20.6M in Q4 2021.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.